Online first
Review paper
Published online: 2024-09-23

open access

Page views 236
Article views/downloads 96
Get Citation

Connect on Social Media

Connect on Social Media

Thyroid cancer and autoimmune connective tissue disorders

Maria Aleksandra Komisarz-Calik1, Alicja Hubalewska-Dydejczyk1, Bogdan Batko2, Małgorzata Trofimiuk-Müldner1

Abstract

There are substantial data confirming the association between autoimmune disorders, including connective tissue diseases (CTDs), and an increased risk of thyroid malignancy. CTDs and thyroid cancer may co-exist as 2 separate diseases because of their relatively high incidence rates in the population. They can arise from each other due to the increased risk of thyroid cancer in patients with idiopathic inflammatory myositis, rheumatoid arthritis, systemic sclerosis, primary Sjögren’s syndrome, and systemic lupus erythematosus.

Moreover, in some scarce cases, CTDs may act as the paraneoplastic syndromes of thyroid cancer. The presence of CTDs may impact the diagnostic process, especially distorting the results of imaging tests or falsely indicating the increase of thyroglobulin or calcitonin. Finally, TSH suppression is a crucial element of the treatment of differentiated thyroid cancer, which may decrease bone mineral density and increase
the risk of osteoporosis by accelerating bone turnover and shortening the bone remodeling cycle.

The aim of this review is to emphasise the vital aspects of this interrelationship. The authors discuss this phenomenon aiming at the explanation of possible linking mechanisms. The impact of selected CTDs on thyroid cancer management is presented, as well as the possible effects of cancer therapy on skeletal health.

Article available in PDF format

View PDF Download PDF file

References

  1. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016; 388(10061): 2783–2795.
  2. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022; 10(4): 264–272.
  3. Cai Y, Zhang J, Liang J, et al. The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis. J Clin Med. 2023; 12(4).
  4. Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021; 60(7): 3121–3133.
  5. Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol. 2014; 6: 247–255.
  6. Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol Int. 2022; 42(12): 2097–2107.
  7. Khoo T, Lilleker JB, Thong BYH, et al. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2023; 19(11): 695–712.
  8. Zhou Z, Liu H, Yang Y, et al. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. Cancer Commun (Lond). 2022; 42(5): 435–446.
  9. Han JY, Kim H, Jung SY, et al. Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea. Arthritis Res Ther. 2021; 23(1): 270.
  10. Hardenbergh D, Naik R, Manno R, et al. The Cancer Risk Profile of Systemic Lupus Erythematosus Patients. J Clin Rheumatol. 2022; 28(1): e257–e262.
  11. Clarke AE, Pooley N, Marjenberg Z, et al. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis. Semin Arthritis Rheum. 2021; 51(6): 1230–1241.
  12. Zhang M, Wang Y, Wang Y, et al. Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies. Front Oncol. 2022; 12: 860794.
  13. Zhong H, Liu S, Wang Y, et al. Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis. Autoimmun Rev. 2022; 21(5): 103084.
  14. Goulabchand R, Malafaye N, Jacot W, et al. Cancer incidence in primary Sjögren's syndrome: Data from the French hospitalization database. Autoimmun Rev. 2021; 20(12): 102987.
  15. Choi HG, Kang HoS, Lim H, et al. Potential Cancer Risk in Patients with Rheumatoid Arthritis: A Longitudinal Korean Population-Based Analysis. J Pers Med. 2022; 12(6).
  16. Lee H. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis. Yonsei Med J. 2019; 60(2): 223–229.
  17. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021; 9(4): 225–234.
  18. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening and overdiagnosis. N Engl J Med. 2014; 371(19): 1765–1767.
  19. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023; 401(10391): 1878–1890.
  20. Sun X, Lu Li, Li Y, et al. Increased risk of thyroid disease in patients with Sjogren's syndrome: a systematic review and meta-analysis. PeerJ. 2019; 7: e6737.
  21. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010; 123(2): 183.e1–183.e9.
  22. Chen YK, Lin CL, Cheng FTF, et al. Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study. Br J Cancer. 2013; 109(9): 2496–2501.
  23. Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res. 2012; 44(4): 255–262.
  24. Boi F, Pani F, Mariotti S. Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological Studies. Eur Thyroid J. 2017; 6(4): 178–186.
  25. Liotti F, Visciano C, Melillo RM. Inflammation in thyroid oncogenesis. Am J Cancer Res. 2012; 2(3): 286–297.
  26. Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007; 28(5): 492–520.
  27. Racanelli V, Prete M, Minoia C, et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008; 7(5): 352–358.
  28. Tabata M, Kobayashi T. Polymyalgia rheumatica and thyroid papillary carcinoma. Intern Med. 1994; 33(1): 41–44.
  29. Kalliabakos D, Pappas A, Lagoudianakis E, et al. A case of polymyositis associated with papillary thyroid cancer: a case report. Cases J. 2008; 1(1): 289.
  30. Yilmaz U, Ugurlu S. Dermatomyositis Associated With Papillary Thyroid Cancer: Systematic Review of the Literature and a Case Report. J Clin Rheumatol. 2021; 27(4): 168–171.
  31. Ahn JK, Oh JM, Lee J, et al. Adult onset Still's disease diagnosed concomitantly with occult papillary thyroid cancer: paraneoplastic manifestation or coincidence? Clin Rheumatol. 2010; 29(2): 221–224.
  32. Inoue R, Kato T, Kim F, et al. A case of adult-onset Still's disease (AOSD)-like manifestations abruptly developing during confirmation of a diagnosis of metastatic papillary thyroid carcinoma. Mod Rheumatol. 2012; 22(5): 796–800.
  33. Tirri R, Capocotta D. Incidental papillary thyroid cancer diagnosis in patient with adult-onset Still's disease-like manifestations. Reumatismo. 2019; 71(1): 42–45.
  34. Tavarelli M, Sarfati J, De Gennes C, et al. Hypertrophic Osteoarthropathy and Follicular Thyroid Cancer: A Rare Paraneoplastic Syndrome. Eur Thyroid J. 2015; 4(4): 266–270.
  35. Guerouaz N, Alaoui M, Raiss M, et al. Systemic paraneoplastic vasculitis secondary to papillary carcinoma of the thyroid. Clin Exp Dermatol. 2016; 41(6): 655–658.
  36. Do H, Pyo JY, Ahn SS, et al. Cancer-associated vasculitides: a single-centre case series. Clin Rheumatol. 2023; 42(1): 151–158.
  37. Hong S, Won YJ, Park YR, et al. Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2017. Cancer Res Treat. 2020; 52(2): 335–350.
  38. Bellini P, Albano D, Dondi F, et al. Incidental radioiodine uptake at whole body scan due to Primary Sjogren Syndrome in a patient with differentiated Thyroid cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022; 41(1): 47–49.
  39. Lupoli GA, Barba L, Liotti A, et al. Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report. Medicine (Baltimore). 2019; 98(5): e14178.
  40. Jarząb B, Dedecjus M, Lewiński A, et al. Diagnosis and treatment of thyroid cancer in adult patients - Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych - Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. Endokrynol Pol. 2022; 73(2): 173–300.
  41. Biondi B, Cooper DS. Thyroid Hormone Suppression Therapy. Endocrinol Metab Clin North Am. 2019; 48(1): 227–237.
  42. Cellini M, Rotondi M, Tanda ML, et al. Skeletal health in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2021; 44(3): 431–442.
  43. Ku EuJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021; 106(12): 3655–3667.
  44. Kwak D, Ha J, Won Y, et al. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021; 11(5): e043007.
  45. Chung CW, Choi HS, Kong SH, et al. Measurements of Bone Health after Thyroid-Stimulating Suppression Therapy in Postmenopausal Women with Differentiated Thyroid Carcinoma: Bone Mineral Density versus the Trabecular Bone Score. J Clin Med. 2021; 10(9).
  46. Ran B, Wei F, Gong J, et al. Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy. Front Endocrinol (Lausanne). 2022; 13: 1004962.
  47. Jin YJ, Song CM, Park BJ, et al. Analyses of the Association between Thyroid Cancer and Osteoporosis/Fracture Histories: A Cross-Sectional Study Using KoGES HEXA Data. Int J Environ Res Public Health. 2021; 18(9).
  48. Lee Y, Yoon BH, Lee S, et al. Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. J Bone Metab. 2019; 26(1): 45–50.
  49. Notsu M, Yamauchi M, Morita M, et al. Papillary thyroid carcinoma is a risk factor for severe osteoporosis. J Bone Miner Metab. 2020; 38(2): 264–270.
  50. Hong AR, Kang HC. Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association. Endocrinol Metab (Seoul). 2023; 38(2): 175–189.